BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Martini S, Donato MF, Mazzarelli C, Rendina M, Visco-Comandini U, Filì D, Gianstefani A, Fagiuoli S, Melazzini M, Montilla S, Pani L, Petraglia S, Russo P, Trotta MP, Carrai P, Caraceni P; ITACOPS study group. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real-life experience. Liver Int 2018;38:733-41. [PMID: 28921807 DOI: 10.1111/liv.13588] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
Number Citing Articles
1 Marcellusi A, Viti R, Kondili LA, Rosato S, Vella S, Mennini FS; PITER Collaborating group available at www.progettopiter.it. Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data. Pharmacoeconomics 2019;37:255-66. [PMID: 30378086 DOI: 10.1007/s40273-018-0733-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
2 Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 2018;15:753-64. [DOI: 10.1038/s41575-018-0045-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
3 Burra P, Giannini EG, Caraceni P, Ginanni Corradini S, Rendina M, Volpes R, Toniutto P. Specific issues concerning the management of patients on the waiting list and after liver transplantation. Liver Int 2018;38:1338-62. [PMID: 29637743 DOI: 10.1111/liv.13755] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]